

L Trevor Young

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10836343/publications.pdf>

Version: 2024-02-01

131
papers

12,344
citations

26630

56
h-index

24982

109
g-index

132
all docs

132
docs citations

132
times ranked

10063
citing authors

#	ARTICLE	IF	CITATIONS
1	Inflammatory markers, brain-derived neurotrophic factor, and the symptomatic course of adolescent bipolar disorder: A prospective repeated-measures study. <i>Brain, Behavior, and Immunity</i> , 2022, 100, 278-286.	4.1	12
2	Prevalence and health care costs of mitochondrial disease in Ontario, Canada: A population-based cohort study. <i>PLoS ONE</i> , 2022, 17, e0265744.	2.5	8
3	Transgender health in medical education. <i>Bulletin of the World Health Organization</i> , 2021, 99, 296-303.	3.3	36
4	Three visions of doctoring: a Gadamerian dialogue. <i>Advances in Health Sciences Education</i> , 2019, 24, 403-412.	3.3	9
5	DNA redox modulations and global DNA methylation in bipolar disorder: Effects of sex, smoking and illness state. <i>Psychiatry Research</i> , 2018, 261, 589-596.	3.3	22
6	Bipolar Disorder as a Mitochondrial Disease. <i>Biological Psychiatry</i> , 2018, 83, 720-721.	1.3	33
7	Analysis of the Influence of microRNAs in Lithium Response in Bipolar Disorder. <i>Frontiers in Psychiatry</i> , 2018, 9, 207.	2.6	28
8	A Longitudinal Study of the Relationships Between Mood Symptoms, Body Mass Index, and Serum Adipokines in Bipolar Disorder. <i>Journal of Clinical Psychiatry</i> , 2017, 78, 441-448.	2.2	18
9	Dentate gyrusâ€™ cornu ammonis (CA) 4 volume is decreased and associated with depressive episodes and lipid peroxidation in bipolar <sc>ll</sc> disorder: Longitudinal and crossâ€™sectional analyses. <i>Bipolar Disorders</i> , 2016, 18, 657-668.	1.9	17
10	Decreased Brain-Derived Neurotrophic Factor in Older Adults with Bipolar Disorder. <i>American Journal of Geriatric Psychiatry</i> , 2016, 24, 596-601.	1.2	23
11	Neuropathological relationship between major depression and dementia: A hypothetical model and review. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2016, 67, 51-57.	4.8	89
12	Association of peripheral inflammation with body mass index and depressive relapse in bipolar disorder. <i>Psychoneuroendocrinology</i> , 2016, 65, 76-83.	2.7	37
13	Genetic variants associated with response to lithium treatment in bipolar disorder: a genome-wide association study. <i>Lancet, The</i> , 2016, 387, 1085-1093.	13.7	306
14	Nod-like receptor pyrin containing 3 (NLRP3) in the post-mortem frontal cortex from patients with bipolar disorder: A potential mediator between mitochondria and immune-activation. <i>Journal of Psychiatric Research</i> , 2016, 72, 43-50.	3.1	104
15	Regulators of mitochondrial complex I activity: A review of literature and evaluation in postmortem prefrontal cortex from patients with bipolar disorder. <i>Psychiatry Research</i> , 2016, 236, 148-157.	3.3	8
16	Understanding the Neurobiology of Bipolar Depression. <i>Milestones in Drug Therapy</i> , 2016, , 93-114.	0.1	1
17	Getting to wellness: The potential of the athletic model of marginal gains for the treatment of bipolar disorder. <i>Australian and New Zealand Journal of Psychiatry</i> , 2015, 49, 1207-1214.	2.3	21
18	Glutathione-mediated effects of lithium in decreasing protein oxidation induced by mitochondrial complex I dysfunction. <i>Journal of Neural Transmission</i> , 2015, 122, 741-746.	2.8	6

#	ARTICLE	IF	CITATIONS
19	CACNA1C rs1006737 genotype and bipolar disorder: Focus on intermediate phenotypes and cardiovascular comorbidity. <i>Neuroscience and Biobehavioral Reviews</i> , 2015, 55, 198-210.	6.1	33
20	Reply. <i>Acta Psychiatrica Scandinavica</i> , 2015, 131, 397-398.	4.5	0
21	Combined treatment: impact of optimal psychotherapy and medication in bipolar disorder. <i>Bipolar Disorders</i> , 2015, 17, 86-96.	1.9	19
22	Oxidative Stress in Older Patients with Bipolar Disorder. <i>American Journal of Geriatric Psychiatry</i> , 2015, 23, 314-319.	1.2	34
23	Decreased global methylation in patients with bipolar disorder who respond to lithium. <i>International Journal of Neuropsychopharmacology</i> , 2014, 17, 561-569.	2.1	59
24	Oxidation and nitration in dopaminergic areas of the prefrontal cortex from patients with bipolar disorder and schizophrenia. <i>Journal of Psychiatry and Neuroscience</i> , 2014, 39, 276-285.	2.4	48
25	The neurobiology of bipolar disorder: identifying targets for specific agents and synergies for combination treatment. <i>International Journal of Neuropsychopharmacology</i> , 2014, 17, 1039-1052.	2.1	58
26	An updated meta-analysis of oxidative stress markers in bipolar disorder. <i>Psychiatry Research</i> , 2014, 218, 61-68.	3.3	266
27	Vitis labrusca extract effects on cellular dynamics and redox modulations in a SH-SY5Y neuronal cell model: A similar role to lithium. <i>Neurochemistry International</i> , 2014, 79, 12-19.	3.8	13
28	Lithium reduces the effects of rotenone-induced complex I dysfunction on DNA methylation and hydroxymethylation in rat cortical primary neurons. <i>Psychopharmacology</i> , 2014, 231, 4189-4198.	3.1	33
29	Immunological and neurotrophic markers of risk status and illness development in high-risk youth: understanding the neurobiological underpinnings of bipolar disorder. <i>International Journal of Bipolar Disorders</i> , 2014, 2, 29.	2.2	29
30	Abstinence from repeated amphetamine treatment induces depressive-like behaviors and oxidative damage in rat brain. <i>Psychopharmacology</i> , 2013, 227, 605-614.	3.1	19
31	Biomarkers in bipolar disorder: A positional paper from the International Society for Bipolar Disorders Biomarkers Task Force. <i>Australian and New Zealand Journal of Psychiatry</i> , 2013, 47, 321-332.	2.3	193
32	Alterations in phosphorylated cAMP response element-binding protein (pCREB) signaling: an endophenotype of lithium-responsive bipolar disorder?. <i>Bipolar Disorders</i> , 2013, 15, 824-831.	1.9	20
33	Toward Clinically Applicable Biomarkers in Bipolar Disorder: Focus on BDNF, Inflammatory Markers, and Endothelial Function. <i>Current Psychiatry Reports</i> , 2013, 15, 425.	4.5	66
34	Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. <i>Bipolar Disorders</i> , 2013, 15, 1-44.	1.9	740
35	The evolution of CANMAT Bipolar Disorder Guidelines: past, present, and future. <i>Bipolar Disorders</i> , 2013, 15, 58-60.	1.9	14
36	Response to commentaries on the Canadian Network for Mood and Anxiety Treatments/International Society for Bipolar Disorders 2013 updated Bipolar Disorder Guidelines. <i>Bipolar Disorders</i> , 2013, 15, 338-339.	1.9	1

#	ARTICLE	IF	CITATIONS
37	Brain Structural Signature of Familial Predisposition for Bipolar Disorder: Replicable Evidence For Involvement of the Right Inferior Frontal Gyrus. <i>Biological Psychiatry</i> , 2013, 73, 144-152.	1.3	118
38	A Fresh Look at Complex I in Microarray Data: Clues to Understanding Disease-Specific Mitochondrial Alterations in Bipolar Disorder. <i>Biological Psychiatry</i> , 2013, 73, e4-e5.	1.3	62
39	Number of manic episodes is associated with elevated DNA oxidation in bipolar I disorder. <i>International Journal of Neuropsychopharmacology</i> , 2013, 16, 1505-1512.	2.1	73
40	Mood stabilizer lithium inhibits amphetamine-increased 4-hydroxynonenal-protein adducts in rat frontal cortex. <i>International Journal of Neuropsychopharmacology</i> , 2012, 15, 1275-1285.	2.1	30
41	Hippocampal volumes in bipolar disorders: opposing effects of illness burden and lithium treatment. <i>Bipolar Disorders</i> , 2012, 14, 261-270.	1.9	99
42	Brain glutamate levels measured by magnetic resonance spectroscopy in patients with bipolar disorder: a meta-analysis. <i>Bipolar Disorders</i> , 2012, 14, 478-487.	1.9	184
43	A Randomized Controlled Trial of Psychoeducation or Cognitive-Behavioral Therapy in Bipolar Disorder. <i>Journal of Clinical Psychiatry</i> , 2012, 73, 803-810.	2.2	111
44	Prefrontal cortex glutathione S-transferase levels in patients with bipolar disorder, major depression and schizophrenia. <i>International Journal of Neuropsychopharmacology</i> , 2011, 14, 1069-1074.	2.1	84
45	Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders. <i>International Journal of Neuropsychopharmacology</i> , 2011, 14, 123-130.	2.1	462
46	Implication of synapse-related genes in bipolar disorder by linkage and gene expression analyses. <i>International Journal of Neuropsychopharmacology</i> , 2010, 13, 1397-1410.	2.1	47
47	Oxidative damage to RNA but not DNA in the hippocampus of patients with major mental illness. <i>Journal of Psychiatry and Neuroscience</i> , 2010, 35, 296-302.	2.4	132
48	Mitochondrial Complex I Activity and Oxidative Damage to Mitochondrial Proteins in the Prefrontal Cortex of Patients With Bipolar Disorder. <i>Archives of General Psychiatry</i> , 2010, 67, 360.	12.3	382
49	The International Consortium on Lithium Genetics (ConLiGen): An Initiative by the NIMH and IGSLI to Study the Genetic Basis of Response to Lithium Treatment. <i>Neuropsychobiology</i> , 2010, 62, 72-78.	1.9	134
50	Signal Transduction Pathways in the Pathophysiology of Bipolar Disorder. <i>Current Topics in Behavioral Neurosciences</i> , 2010, 5, 139-165.	1.7	3
51	Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. <i>Bipolar Disorders</i> , 2009, 11, 225-255.	1.9	545
52	Increased oxidative stress in the anterior cingulate cortex of subjects with bipolar disorder and schizophrenia. <i>Bipolar Disorders</i> , 2009, 11, 523-529.	1.9	217
53	Marcadores de estrés oxidativo en el trastorno bipolar: un metaanálisis. <i>Psiquiatria Biologica</i> , 2009, 16, 60-69.	0.1	0
54	Mood stabilizing drugs lamotrigine and olanzapine increase expression and activity of glutathione s-transferase in primary cultured rat cerebral cortical cells. <i>Neuroscience Letters</i> , 2009, 455, 70-73.	2.1	19

#	ARTICLE	IF	CITATIONS
55	Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder. <i>International Journal of Neuropsychopharmacology</i> , 2009, 12, 447.	2.1	343
56	Accelerated age-related decrease in brain-derived neurotrophic factor levels in bipolar disorder. <i>International Journal of Neuropsychopharmacology</i> , 2009, 12, 137.	2.1	46
57	Understanding the neurobiology of bipolar depression. , 2009, , 77-94.		1
58	3-Nitrotyrosine and glutathione antioxidant system in patients in the early and late stages of bipolar disorder. <i>Journal of Psychiatry and Neuroscience</i> , 2009, 34, 263-71.	2.4	140
59	Gene expression differences in bipolar disorder revealed by cDNA array analysis of post-mortem frontal cortex. <i>Journal of Neurochemistry</i> , 2008, 79, 826-834.	3.9	87
60	Lithium response and genetic variation in the CREB family of genes. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2008, 147B, 500-504.	1.7	80
61	Oxidative stress markers in bipolar disorder: A meta-analysis. <i>Journal of Affective Disorders</i> , 2008, 111, 135-144.	4.1	442
62	Bilateral Hippocampal Volume Increase in Patients with Bipolar Disorder and Short-term Lithium Treatment. <i>Neuropsychopharmacology</i> , 2008, 33, 361-367.	5.4	187
63	BDNF protein levels are decreased in transformed lymphoblasts from lithium-responsive patients with bipolar disorder. <i>Journal of Psychiatry and Neuroscience</i> , 2008, 33, 449-53.	2.4	29
64	What is the best treatment for bipolar depression?. <i>Journal of Psychiatry and Neuroscience</i> , 2008, 33, 487-8.	2.4	3
65	Immunoreactivity of 43kDa growth-associated protein is decreased in post mortem hippocampus of bipolar disorder and schizophrenia. <i>Neuroscience Letters</i> , 2007, 411, 123-127.	2.1	34
66	Applying Molecular Approaches to Understand the Etiology and Treatment of Bipolar Disorder. <i>Canadian Journal of Psychiatry</i> , 2007, 52, 751-752.	1.9	1
67	Decreased expression of insulin-like growth factor binding protein 2 in the prefrontal cortex of subjects with bipolar disorder and its regulation by lithium treatment. <i>Brain Research</i> , 2007, 1147, 213-217.	2.2	32
68	Bilateral hippocampal volume increases after long-term lithium treatment in patients with bipolar disorder: a longitudinal MRI study. <i>Psychopharmacology</i> , 2007, 195, 357-367.	3.1	186
69	Neuron somal size is decreased in the lateral amygdalar nucleus of subjects with bipolar disorder. <i>Journal of Psychiatry and Neuroscience</i> , 2007, 32, 203-10.	2.4	48
70	Is bipolar disorder a mitochondrial disease?. <i>Journal of Psychiatry and Neuroscience</i> , 2007, 32, 160-1.	2.4	33
71	Mood stabilizing drug lithium increases expression of endoplasmic reticulum stress proteins in primary cultured rat cerebral cortical cells. <i>Life Sciences</i> , 2006, 78, 1317-1323.	4.3	81
72	Insulin-like growth factor binding protein-2 expression is decreased by lithium. <i>NeuroReport</i> , 2006, 17, 897-901.	1.2	10

#	ARTICLE	IF	CITATIONS
73	Risk and Resilience Markers in Bipolar Disorder: Brain Responses to Emotional Challenge in Bipolar Patients and Their Healthy Siblings. <i>American Journal of Psychiatry</i> , 2006, 163, 257-264.	7.2	113
74	Assessment of Patients with Bipolar Disorder. , 2006, , 51-69.		0
75	Downregulation in components of the mitochondrial electron transport chain in the postmortem frontal cortex of subjects with bipolar disorder. <i>Journal of Psychiatry and Neuroscience</i> , 2006, 31, 189-96.	2.4	151
76	Course of Illness, Hippocampal Function, and Hippocampal Volume in Major Depression. <i>Focus (American Psychiatric Publishing)</i> , 2005, 3, 146-155.	0.8	10
77	Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. <i>Bipolar Disorders</i> , 2005, 7, 5-69.	1.9	321
78	Investigating responders to lithium prophylaxis as a strategy for mapping susceptibility genes for bipolar disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2005, 29, 1038-1045.	4.8	56
79	Chronic Treatment with Mood Stabilizers Lithium and Valproate Prevents Excitotoxicity by Inhibiting Oxidative Stress in Rat Cerebral Cortical Cells. <i>Biological Psychiatry</i> , 2005, 58, 879-884.	1.3	185
80	Identification of Lithium-Regulated Genes in Cultured Lymphoblasts of Lithium Responsive Subjects with Bipolar Disorder. <i>Neuropsychopharmacology</i> , 2004, 29, 799-804.	5.4	56
81	Stress-induced structural remodeling in hippocampus: Prevention by lithium treatment. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 3973-3978.	7.1	179
82	Regulation of molecular chaperone GRP78 by mood stabilizing drugs. <i>Clinical Neuroscience Research</i> , 2004, 4, 281-288.	0.8	7
83	Glutathione Sâ€transferase is a novel target for mood stabilizing drugs in primary cultured neurons. <i>Journal of Neurochemistry</i> , 2004, 88, 1477-1484.	3.9	65
84	Amygdala cyclic adenosine monophosphate response element binding protein phosphorylation in patients with mood disorders: effects of diagnosis, suicide, and drug treatment. <i>Biological Psychiatry</i> , 2004, 55, 570-577.	1.3	50
85	What exactly is a mood stabilizer?. <i>Journal of Psychiatry and Neuroscience</i> , 2004, 29, 87-8.	2.4	12
86	Longitudinal outcome in patients with bipolar disorder assessed by life-charting is influenced by DSM-IV personality disorder symptoms. <i>Bipolar Disorders</i> , 2003, 5, 14-21.	1.9	38
87	Subsyndromal symptoms assessed in longitudinal, prospective followâ€up of a cohort of patients with bipolar disorder. <i>Bipolar Disorders</i> , 2003, 5, 349-355.	1.9	131
88	Regulation of GAP-43 expression by chronic desipramine treatment in rat cultured hippocampal cells. <i>Biological Psychiatry</i> , 2003, 53, 530-537.	1.3	50
89	Acute and chronic restraint stress alter the incidence of social conflict in male rats. <i>Hormones and Behavior</i> , 2003, 43, 205-213.	2.1	123
90	Course of illness, hippocampal function, and hippocampal volume in major depression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 1387-1392.	7.1	854

#	ARTICLE	IF	CITATIONS
91	Chronic Lithium Treatment Inhibits Pilocarpine-Induced Mossy Fiber Sprouting in Rat Hippocampus. <i>Neuropsychopharmacology</i> , 2003, 28, 1448-1453.	5.4	17
92	The Neurobiology of Bipolar Disorder: Focus on Signal Transduction Pathways and the Regulation of Gene Expression. <i>Canadian Journal of Psychiatry</i> , 2002, 47, 135-148.	1.9	65
93	Newer Antiepileptic Drugs in Bipolar Disorder. <i>CNS Drugs</i> , 2002, 16, 549-562.	5.9	188
94	Lamotrigine Increases Gene Expression of GABA-A Receptor $\alpha 2\beta 3$ Subunit in Primary Cultured Rat Hippocampus Cells. <i>Neuropsychopharmacology</i> , 2002, 26, 415-421.	5.4	29
95	Structural plasticity and neuronal resilience: are these targets for mood stabilizers and antidepressants in the treatment of bipolar disorder?. <i>Bipolar Disorders</i> , 2002, 4, 77-79.	1.9	1
96	Regulation of ER stress proteins by valproate: therapeutic implications. <i>Bipolar Disorders</i> , 2002, 4, 145-151.	1.9	69
97	Previous mood state predicts response and switch rates in patients with bipolar depression. <i>Acta Psychiatrica Scandinavica</i> , 2002, 105, 414-418.	4.5	30
98	The neurobiology of treatment response to antidepressants and mood stabilizing medications. <i>Journal of Psychiatry and Neuroscience</i> , 2002, 27, 260-5.	2.4	27
99	Identification of mood stabilizer-regulated genes by differential-display PCR. <i>International Journal of Neuropsychopharmacology</i> , 2001, 4, 65-74.	2.1	25
100	G Protein-Coupled Cyclic AMP Signaling in Postmortem Brain of Subjects with Mood Disorders. <i>Journal of Neurochemistry</i> , 2001, 73, 1121-1126.	3.9	122
101	A review of psychosocial outcome in patients with bipolar disorder. <i>Acta Psychiatrica Scandinavica</i> , 2001, 103, 163-170.	4.5	286
102	Bipolar II Disorder: Symptoms, Course, and Response to Treatment. <i>Psychiatric Services</i> , 2001, 52, 358-361.	2.0	63
103	Increased hippocampal supragranular Timm staining in subjects with bipolar disorder. <i>NeuroReport</i> , 2000, 11, 3775-3778.	1.2	41
104	Effect of number of episodes on wellbeing and functioning of patients with bipolar disorder. <i>Acta Psychiatrica Scandinavica</i> , 2000, 101, 374-381.	4.5	130
105	Double-Blind Comparison of Addition of a Second Mood Stabilizer Versus an Antidepressant to an Initial Mood Stabilizer for Treatment of Patients With Bipolar Depression. <i>American Journal of Psychiatry</i> , 2000, 157, 124-126.	7.2	207
106	Molecular Abnormalities in Brains of Depressed Patients. <i>Neuroscientist</i> , 2000, 6, 401-410.	3.5	0
107	Number of episodes and antidepressant response in major depression. <i>International Journal of Neuropsychopharmacology</i> , 1999, 2, 111-113.	2.1	8
108	Platelet Protein Kinase C α Levels in Drug-Free and Lithium-Treated Subjects with Bipolar Disorder. <i>Neuropsychobiology</i> , 1999, 40, 63-66.	1.9	27

#	ARTICLE	IF	CITATIONS
109	A two-illness model of bipolar disorder 1. <i>Bipolar Disorders</i> , 1999, 1, 25-30.	1.9	51
110	Gabapentin as an adjunctive treatment in bipolar disorder. <i>Journal of Affective Disorders</i> , 1999, 55, 73-77.	4.1	46
111	Increased temporal cortex CREB concentrations and antidepressant treatment in major depression. <i>Lancet, The</i> , 1998, 352, 1754-1755.	13.7	270
112	Increased G α q/11 immunoreactivity in postmortem occipital cortex from patients with bipolar affective disorder. <i>Biological Psychiatry</i> , 1997, 41, 649-656.	1.3	56
113	Platelet endogenous adenosine 5'-diphosphate ribosylation in drug-free and lithium-treated subjects with bipolar disorder. <i>Biological Psychiatry</i> , 1997, 42, 413-415.	1.3	2
114	Relationship between the five-factor model of personality and unipolar, bipolar and schizophrenic patients. <i>Psychiatry Research</i> , 1997, 70, 83-94.	3.3	149
115	Quantification of Neuroreceptors in the Living Human Brain: IV. Effect of Aging and Elevations of D2-Like Receptors in Schizophrenia and Bipolar Illness. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1997, 17, 331-342.	4.3	117
116	Reduced [³ H]Cyclic AMP Binding in Postmortem Brain from Subjects with Bipolar Affective Disorder. <i>Journal of Neurochemistry</i> , 1997, 68, 297-304.	3.9	94
117	Stimulatory G-protein β -subunit mRNA levels are not increased in autopsied cerebral cortex from patients with bipolar disorder. <i>Molecular Brain Research</i> , 1996, 42, 45-50.	2.3	25
118	The Phosphoinositide Signal Transduction System Is Impaired in Bipolar Affective Disorder Brain. <i>Journal of Neurochemistry</i> , 1996, 66, 2402-2409.	3.9	110
119	Bipolar II: Not so different when comorbidity excluded. <i>Depression</i> , 1995, 3, 154-156.	0.6	29
120	Prior antidepressant treatment does not have an impact on response to desipramine treatment in major depression. <i>Biological Psychiatry</i> , 1995, 38, 410-412.	1.3	5
121	"Double bipolar disorder": A separate entity?. <i>Depression</i> , 1994, 2, 223-225.	0.6	5
122	CNS signal transduction in the pathophysiology and pharmacotherapy of affective disorders and schizophrenia. <i>Synapse</i> , 1993, 13, 278-293.	1.2	153
123	Cerebral Cortex Gs β Protein Levels and Forskolin-Stimulated Cyclic AMP Formation Are Increased in Bipolar Affective Disorder. <i>Journal of Neurochemistry</i> , 1993, 61, 890-898.	3.9	161
124	Elevated Stimulatory and Reduced Inhibitory G Protein β Subunits in Cerebellar Cortex of Patients with Dominantly Inherited Olivopontocerebellar Atrophy. <i>Journal of Neurochemistry</i> , 1993, 60, 1816-1820.	3.9	9
125	Anxious and non-anxious bipolar disorder. <i>Journal of Affective Disorders</i> , 1993, 29, 49-52.	4.1	159
126	Regional distribution of guanine nucleotide binding proteins (Gs and Gi β) in human brain: correlation with adenylyl cyclase activity. <i>Neurochemistry International</i> , 1993, 22, 285-291.	3.8	12

#	ARTICLE	IF	CITATIONS
127	Psychiatric Consultation in the Eastern Canadian Arctic: I. Development and Evolution of the Baffin Psychiatric Consultation Service. Canadian Journal of Psychiatry, 1993, 38, 23-27.	1.9	5
128	Psychiatric Consultation in the Eastern Canadian Arctic: II. Referral Patterns, Diagnoses and Treatment. Canadian Journal of Psychiatry, 1993, 38, 28-31.	1.9	38
129	Psychiatric Consultation in the Eastern Canadian Arctic: III. Mental Health Issues in Inuit Women in the Eastern Arctic. Canadian Journal of Psychiatry, 1993, 38, 32-35.	1.9	9
130	Maturation and aging effects on guanine nucleotide binding protein immunoreactivity in human brain. Developmental Brain Research, 1991, 61, 243-248.	1.7	53
131	Effects of endogenous dopamine on kinetics of [3H]N-methylspiperone and [3H]raclopride binding in the rat brain. Synapse, 1991, 9, 188-194.	1.2	126